What's Happening?
A preclinical study has evaluated AL-001, a gene therapy for wet age-related macular degeneration (wAMD), demonstrating its potential to provide sustained therapeutic effects. AL-001 utilizes a recombinant adeno-associated viral vector to deliver aflibercept,
a protein that inhibits vascular endothelial growth factor (VEGF), directly to the eye. The study compared suprachoroidal space (SCS) and intravitreal (IVT) administration in animal models, finding that SCS delivery resulted in sustained aflibercept expression with reduced inflammation and improved efficacy. These findings suggest that AL-001 could offer a long-acting treatment option for wAMD, reducing the need for frequent injections.
Why It's Important?
Wet age-related macular degeneration is a leading cause of vision loss in older adults, and current treatments require frequent injections, which can be burdensome for patients. The development of AL-001 as a gene therapy offers a promising alternative, potentially reducing treatment frequency while maintaining efficacy. This advancement could significantly improve the quality of life for patients with wAMD and reduce healthcare costs associated with frequent treatments. The study's results support further clinical development of AL-001, highlighting the potential of gene therapy to transform the management of chronic eye diseases.
